



533 Rec'd PCT/PT 11 AUG 2000

PCT #3

PATENT
Docket No. 220002058901
Client Ref. INSEL UC 98-021-1

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on August 7, 2000.

Patricia Ellison
Patricia Ellison

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Paul A. INSEL et al.

Serial No.: 09/402,244

371 Application Filing Date: September 29, 1999

371 102(e) Date: Not Yet Assigned

For: METHODS AND COMPOSITIONS FOR
IDENTIFYING VARIATIONS IN
HUMAN α_{1B} - AND β_2 -ADRENERGIC
RECEPTOR GENES

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and

authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 220002058901. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.


Dated: August 7, 2000

Respectfully submitted,

By: Catherine M. Polizzi
Catherine M. Polizzi
Registration No. 40,130

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5651
Facsimile: (650) 494-0792

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 220002058901	Application Number 09/402,244
	Applicant Paul A. INSEL et al.	
	371 Application Filing Date September 29, 1999	Group Art Unit Not Yet Assigned
	371 102(e) Date: Not Yet Assigned	
Mailing Date August 7, 2000		



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/28/1987	4,683,195	Mullis et al.			
	2.	09/17/1996	5,556,753	Bard et al.			
	3.	11/26/1996	5,578,611	Gluchowski et al.			
	4.	02/03/1998	5,714,381	Bard et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	5.	04/14/1994	WO 94/08040 A1	PCT			
	6.	10/26/1995	WO 95/28397 A1	PCT			
	7.	10/02/1997	WO 97/35963 A1	PCT			Abstract only
	8.	04/22/1999	WO 99/19512 A1	PCT			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)


Examiner Initials	Ref. No.	Title
	9.	Ahlquist. (1948). "A study of the adrenotropic receptors," <i>Am. J. Physiol.</i> 153:586-600.
	10.	Billman. (1994). "Effect of α_1 -adrenergic receptor antagonists on susceptibility to malignant arrhythmias: protection from ventricular fibrillation," <i>J. Cardiovas. Pharmacol.</i> 24:394-402.
	11.	Cavalli et al. (1997). "Decreased blood pressure response in mice deficient of the α_{1b} -adrenergic receptor," <i>Proc. Natl. Acad. Sci. USA</i> 94:11589-11594.
	12.	Cotton. (1992). "Detection of mutations in DNA," <i>Curr. Opin. in Biot.</i> 3:24-30.
	13.	Emorine et al. (1987). "Structure of the gene for human β_2 -adrenergic receptor: expression and promoter characterization," <i>Proc. Natl. Acad. Sci. USA</i> 84:6995-6999.
	14.	Gaidano et al. (1991). "p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia," <i>Proc. Natl. Acad. Sci. USA</i> 88:5413-5417.
	15.	Guarino et al. (1996). "Recent advances in the molecular pharmacology of the α_1 -adrenergic receptors," <i>Cell. Signal.</i> 8(5):323-333.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 220002058901	Application Number 09/402,244
	Applicant Paul A. INSEL et al.	
	371 Application Filing Date September 29, 1999	Group Art Unit Not Yet Assigned
	371 102(e) Date: Not Yet Assigned	
Mailing Date August 7, 2000		



OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	16.	Insel. (1996). "Adrenergic receptors-evolving concepts and clinical implications," <i>New Engl. J. Med.</i> 334:580-585.
	17.	Kobilka et al. (1987). "cDNA for the human β_2 -adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor," <i>Proc. Natl. Acad. Sci. USA</i> 84:46-50.
	18.	Kotanko et al. (1997). "Essential hypertension in African Carribeans associates with a variant of the β_2 -andrenoceptor," <i>Hypertension</i> 30(4):773-776.
	19.	Ledent et al. (1997). "Costimulation of adenylyl cyclase and phospholipase C by a mutant α_{1B} -adrenergic receptor transgene promotes malignant transformation of thyroid follicular cells," <i>Endocrinology</i> 138(1):369-378.
	20.	Liggett et al. (1995). "Genetics of β_2 -adrenergic receptor variants in asthma," <i>Clinical and Experimental Allergy</i> 25(2):89-94.
	21.	Michel et al. (1989). "Renel α -adrenergic receptor alterations: a cause of essential hypertension," <i>FASEB J.</i> 3:139-144.
	22.	Ohe et al. (1995). "Beta ₂ adrenergic receptor gene restriction fragment length polymorphism and bronchial asthma," <i>Thorax</i> 50:353-359.
	23.	Orita et al. (1989). "Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms," <i>Proc. Natl. Sci. USA</i> 86:2766-2770.
	24.	Ramarao et al. (1992). "Genomic organization and expression of the human α_{1B} adrenergic receptor" <i>J. Biol. Chem.</i> 267(30):21936-21945.
	25.	Raymond et al. (1990). "Adrenergic receptors: models for regulation of signal transduction processes," <i>Hypertension</i> 15(2):119-131.
	26.	Sheppard et al. (1983). "Chromosomal assignment of the gene for the human β_2 -adrenergic receptor," <i>Proc. Natl. Acad. Sci. USA</i> 80:233-236.
	27.	Shibata et al. (1996). " α_{1a} -andrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy," <i>Br. J. Pharmacol.</i> 118:1403-1408.
	28.	Svetkey et al. (1996). "Association of hypertension with β_2 - and α_{2c10} -adrenergic receptor genotype," <i>Hypertension</i> 27:1210-1215.
	29.	Turki et al. (1995). "Genetic polymorphisms of the β_2 -adrenergic receptor in nocturnal and nonnocturnal asthma," <i>J. Clin. Invest.</i> 95:1635-1641.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	